Sunflower Pharmaceutical Group Co.,Ltd (SHE:002737)
China · Delayed Price · Currency is CNY 13.10
+0.28 (2.18%)
Apr 29, 2026, 3:04 PM CST
SHE:002737 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,318 | 3,362 | 5,686 | 5,083 | 4,454 |
Other Revenue | - | 14.94 | 14.62 | 11.03 | 6.55 |
| 2,318 | 3,377 | 5,700 | 5,095 | 4,461 | |
Revenue Growth (YoY) | -31.36% | -40.76% | 11.89% | 14.20% | 28.86% |
Cost of Revenue | 1,434 | 1,896 | 2,493 | 2,157 | 1,822 |
Gross Profit | 884.35 | 1,481 | 3,208 | 2,938 | 2,639 |
Selling, General & Admin | 1,000 | 854.08 | 1,839 | 1,751 | 1,643 |
Research & Development | 111.11 | 124.13 | 128.65 | 94.61 | 132.07 |
Other Operating Expenses | -14.92 | 42.25 | 60.82 | 69.4 | 65.56 |
Operating Expenses | 1,096 | 1,028 | 2,024 | 1,916 | 1,867 |
Operating Income | -212.03 | 452.83 | 1,184 | 1,022 | 771.33 |
Interest Expense | - | -3.56 | -5.97 | -9.73 | -10.19 |
Interest & Investment Income | 31.05 | 52.21 | 85.35 | 30.56 | 44.09 |
Currency Exchange Gain (Loss) | - | 0.05 | -0.09 | 0.11 | - |
Other Non Operating Income (Expenses) | -9.74 | 1.08 | -2.42 | -4.56 | -0.24 |
EBT Excluding Unusual Items | -190.73 | 502.61 | 1,260 | 1,039 | 805 |
Impairment of Goodwill | - | -4.8 | - | -15.83 | -27.22 |
Gain (Loss) on Sale of Investments | 3.89 | -12.99 | -16.39 | -19.31 | 2.67 |
Gain (Loss) on Sale of Assets | -0.65 | -0.24 | 3.23 | 7.43 | 47.77 |
Asset Writedown | -83.67 | -20.99 | -0.48 | -10.6 | -2.46 |
Other Unusual Items | - | 170.89 | 108.02 | 80.63 | 68.76 |
Pretax Income | -271.15 | 634.49 | 1,355 | 1,081 | 894.51 |
Income Tax Expense | 25.92 | 131.76 | 189.83 | 171.37 | 132.16 |
Earnings From Continuing Operations | -297.07 | 502.73 | 1,165 | 909.73 | 762.35 |
Minority Interest in Earnings | 39.25 | -10.69 | -45.8 | -42.51 | -57.61 |
Net Income | -257.83 | 492.05 | 1,119 | 867.22 | 704.74 |
Net Income to Common | -257.83 | 492.05 | 1,119 | 867.22 | 704.74 |
Net Income Growth | - | -56.03% | 29.05% | 23.06% | 20.58% |
Shares Outstanding (Basic) | 586 | 586 | 583 | 586 | 582 |
Shares Outstanding (Diluted) | 586 | 586 | 583 | 586 | 582 |
Shares Change (YoY) | 0.03% | 0.49% | -0.53% | 0.61% | -0.35% |
EPS (Basic) | -0.44 | 0.84 | 1.92 | 1.48 | 1.21 |
EPS (Diluted) | -0.44 | 0.84 | 1.92 | 1.48 | 1.21 |
EPS Growth | - | -56.25% | 29.73% | 22.31% | 21.00% |
Free Cash Flow | 478.86 | -400.27 | 740.52 | 1,822 | 746.92 |
Free Cash Flow Per Share | 0.82 | -0.68 | 1.27 | 3.11 | 1.28 |
Dividend Per Share | - | 0.500 | 1.500 | 1.000 | 0.700 |
Dividend Growth | - | -66.67% | 50.00% | 42.86% | 100.00% |
Gross Margin | 38.15% | 43.85% | 56.27% | 57.67% | 59.15% |
Operating Margin | -9.15% | 13.41% | 20.76% | 20.07% | 17.29% |
Profit Margin | -11.12% | 14.57% | 19.63% | 17.02% | 15.80% |
Free Cash Flow Margin | 20.66% | -11.85% | 12.99% | 35.77% | 16.74% |
EBITDA | -43.71 | 625.66 | 1,358 | 1,285 | 935.8 |
EBITDA Margin | -1.89% | 18.53% | 23.83% | 25.22% | 20.98% |
D&A For EBITDA | 168.32 | 172.83 | 174.82 | 262.65 | 164.47 |
EBIT | -212.03 | 452.83 | 1,184 | 1,022 | 771.33 |
EBIT Margin | -9.15% | 13.41% | 20.76% | 20.07% | 17.29% |
Effective Tax Rate | - | 20.77% | 14.01% | 15.85% | 14.77% |
Revenue as Reported | - | 3,377 | 5,700 | 5,095 | 4,461 |
Advertising Expenses | - | 217.86 | 1,078 | 1,068 | 115.37 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.